Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pixuvri’s Conditional EU Approval Could Herald The Rise Of Staggered Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

CTI’s conditional EU approval for its non-Hodgkin B-cell lymphoma drug Pixuvri goes against the run of the drug in the US, but reinforces the idea that staggered approvals are on the way in Europe.

You may also be interested in...



Rare EMA-Sanctioned Compassionate Use Program Sends Gilead’s Sofosbuvir To Market Early

Gilead Sciences sofosbuvir for hepatitis C has gained early, but restricted, entry into the EU market as the European Medicines Agency allows compassionate use at Sweden’s request.

CTI’s Pixuvri Flops Again At British NICE, As Discount Fails To Impress

Despite a sizeable price cut, uncertainty surrounding CTI’s non-Hodgkin’s lymphoma therapy Pixuvri has landed it with a second NICE rejection.

Germany’s G-BA Finds No Added Benefit For CTI’s Pixuvri, Exposing Price

Germany’s G-BA lets through Cell Therapeutics’ Pixuvri for aggressive B-cell non-Hodgkin's lymphoma but finds no added benefit over existing therapies, meaning its price could come under pressure.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074119

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel